A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703
Year: 2020
Type: article
Abstract: Effective immunosuppressive regimens to prevent the development of graft-versus-host disease (GVHD) are essential to the success of allogeneic hematopoietic cell transplantation (HCT). After revolutionizing haploidentical transplantation, post-transplantation cyclophosphamide (PTCy) is now being evaluated for HCT performed from related and unrelated donors. In this setting, 2 recent randomized studies have demonstrated lower rates of GVHD and superior GVHD-free, relapse-free survival with PTCy compared with conventional GVHD prophylaxis. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is currently conducting a large, randomized phase III, multicenter trial (BMT CTN 1703) comparing PTCy/tacrolimus/mycophenolate mofetil to tacrolimus/methotrexate as GVHD prophylaxis regimens in reduced-intensity allogeneic HCT. Here we review the ongoing study, highlight its importance to the field, and explore the possible implications of its results on clinical practice.
Institutions: Massachusetts General Hospital, The Ohio State University, Mayo Clinic, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Rady Children's Institute for Genomic Medicine, University of Minnesota, University of Minnesota Medical Center, University of North Carolina at Chapel Hill, Mayo Clinic in Arizona, Mayo Clinic Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Awards: G777363952, G9000337469, BMT CTN Core - Mount Sinai Consortium, BMT CTN Core - University of Minnesota, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc., G911192202
OpenAlex ID: W3083855356